Abstract
Clinical trials of the HIFU treatment of liver cancer have been underway in the UK at the Royal Marsden Hospital since December 1997, and at the Churchill Hospital since November 2002. Royal Marsden treatments are undertaken using a prototype device known as the Teleson, while those at the Churchill are performed using the machine produced by the Chongqing HAIFU company in China. Both sites have demonstrated the ability to ablate significant volumes of a tumor within the liver. Despite differences in ultrasound exposure delivery, these treatments have highlighted some of the problems associated with the clinical use of extracorporeal HIFU. These problems lie primarily in the areas of targeting, treatment optimization and monitoring of ablation. These problems will be discussed and potential solutions suggested. [Work funded by the UK Department of Health, the Institute of Cancer Research and UTL.]
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
